Clinical Trial Detail

NCT ID NCT03087019
Title Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

adenoid cystic carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.